Back to Search
VEENA CHARU, M.D.
M.D.
Specialist
NPI: 1568438976Individual
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
A45465(CA)
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
A45465(CA)
Research & Publications (12)
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
PMID 17962619·Oncologist·2007
4-observational
Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
PMID 17602062·Oncologist·2007
3-trial
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
PMID 19601709·Curr Med Res Opin·2009
3-trial
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
PMID 19170225·Cancer·2009
4-observational
Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
PMID 18165618·Oncologist·2007
3-trial
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
PMID 17004515·J Support Oncol·2006
3-trial
Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
PMID 16834839·Curr Med Res Opin·2006
4-observational
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
PMID 16381629·Clin Breast Cancer·2005
2-rct
Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
PMID 16177289·Oncologist·2005
4-observational
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
PMID 15561813·Oncologist·2004
3-trial
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
PMID 14635083·Cancer·2003
3-trial
Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
PMID 12435171·Oncology (Williston Park)·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1801 W ROMNEYA DR, 203
ANAHEIM, CA 92801 - Phone
- (714) 999-1465
Quick Facts
- NPI
- 1568438976
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 12
Are you this provider?
Claim Your Profile